Your browser doesn't support javascript.
A multi-institutional partnership catalyzing the commercialization of medical devices and biotechnology products.
Hafer, Nathaniel; Buchholz, Bryan; Dunlap, Denise; Fournier, Brennan; Latham, Scott; Picard, Mary Ann; Tello, Steven; Gibson, Laura; Lilly, Craig M; McManus, David D.
  • Hafer N; UMass Center for Clinical and Translational Science, Worcester, MA, USA.
  • Buchholz B; Massachusetts Medical Device Development Center, Lowell, MA, USA.
  • Dunlap D; Program in Molecular Medicine, UMass Medical School, Worcester, MA, USA.
  • Fournier B; Massachusetts Medical Device Development Center, Lowell, MA, USA.
  • Latham S; Department of Biomedical Engineering, UMass Lowell, Lowell, MA, USA.
  • Picard MA; Massachusetts Medical Device Development Center, Lowell, MA, USA.
  • Tello S; Manning School of Business, UMass Lowell, Lowell, MA, USA.
  • Gibson L; Massachusetts Medical Device Development Center, Lowell, MA, USA.
  • Lilly CM; Massachusetts Medical Device Development Center, Lowell, MA, USA.
  • McManus DD; Manning School of Business, UMass Lowell, Lowell, MA, USA.
J Clin Transl Sci ; 5(1): e119, 2021.
Article in English | MEDLINE | ID: covidwho-1284656
ABSTRACT
The commercialization of medical devices and biotechnology products is characterized by high failure rates and long development lead times particularly among start-up enterprises. To increase the success rate of these high-risk ventures, the University of Massachusetts Lowell (UML) and University of Massachusetts Medical School (UMMS) partnered to create key academic support centers with programs to accelerate entrepreneurship and innovation in this industry. In 2008, UML and UMMS founded the Massachusetts Medical Device Development Center (M2D2), which is a business and technology incubator that provides business planning, product prototyping, laboratory services, access to clinical testing, and ecosystem networking to medical device and biotech start-up firms. M2D2 has three physical locations that encompass approximately 40,000 square feet. Recently, M2D2 leveraged these resources to expand into new areas such as health security, point of care technologies for heart, lung, blood, and sleep disorders, and rapid diagnostics to detect SARS-CoV-2. Since its inception, M2D2 has vetted approximately 260 medical device and biotech start-up companies for inclusion in its programs and provided active support to more than 80 firms. This manuscript describes how two UMass campuses leveraged institutional, state, and Federal resources to create a thriving entrepreneurial environment for medical device and biotech companies.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: J Clin Transl Sci Year: 2021 Document Type: Article Affiliation country: Cts.2021.779

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: J Clin Transl Sci Year: 2021 Document Type: Article Affiliation country: Cts.2021.779